Massivemarkets

SEC Form 4

Boston Scientific Corp. (BSX) insider trading

In the 12 months to Oct 24, 2026, 4 BSX insiders reported open-market sales of $24.3M across 5 filings; 5 insiders bought $10.0M.

Latest filing · Last 12 months · Source: SEC EDGAR · How we count

Open-market sales
$24.3M
5 filings · 4 insiders
Open-market purchases
$10.0M
8 filings
Pre-arranged sales (10b5-1)
5 of 5
All $24.3M sold was pre-arranged

Who traded BSX, and when

  • Purchase
  • Sale
  • Sale, pre-arranged (10b5-1)

BSX daily close from Oct 24, 2025 to Oct 23, 2026, between $41.58 and $104.98, last $45.69. 5 sale and 8 purchase filings by 8 insiders, marked at their filing dates. Michael F. Mahoney, Chairman, President & CEO: sold $15.0M and bought $9.0M across 2 filings, first filed Feb 3, 2026, last Aug 5, 2026. Joseph Michael Fitzgerald, EVP & Group Pres, Cardiology: sold $5.0M across 1 filing, first filed Nov 4, 2025, last Nov 4, 2025. Ellen M. Zane, Director: sold $2.6M across 2 filings, first filed Oct 28, 2025, last Nov 6, 2025. Arthur C. Butcher, EVP& Grp Pres, MedSurg & APAC: sold $1.8M across 1 filing, first filed Dec 2, 2025, last Dec 2, 2025. Edward J. Ludwig, Director: bought $430.3K across 2 filings, first filed May 21, 2026, last Aug 3, 2026. David C. Habiger, Director: bought $407.9K across 3 filings, first filed May 21, 2026, last Aug 7, 2026. Susan E. Morano, Director: bought $100.4K across 1 filing, first filed Aug 26, 2026, last Aug 26, 2026. Cheryl Pegus, Director: bought $100.0K across 1 filing, first filed May 21, 2026, last May 21, 2026.

Largest mark · tap a row for others

Michael F. Mahoney · Chairman, President & CEO

Sale $15,043,394

160,901 shares at $93.49 avg

Filed Feb 3, 2026 · traded Feb 2

Pre-arranged (10b5-1) · close on filing date $91.62

BSX daily closelast $45.69

Michael F. Mahoney · Chairman, President & CEO

$15.0M sold$9.0M bought

Joseph Michael Fitzgerald · EVP & Group Pres, Cardiology

$5.0M sold

Ellen M. Zane · Director

$2.6M sold

Arthur C. Butcher · EVP& Grp Pres, MedSurg & APAC

$1.8M sold

Edward J. Ludwig · Director

$430.3K bought

David C. Habiger · Director

$407.9K bought

Susan E. Morano · Director

$100.4K bought

Cheryl Pegus · Director

$100.0K bought
One row per insider; marks sit at the SEC filing date, sized by dollar value.

Has Boston Scientific Corp.'s CEO sold stock?

Yes. Michael F. Mahoney (CEO) sold 160,901 shares ($15.0M) in Feb 2026, all under a pre-arranged 10b5-1 plan.

Open-market trades

13 filings in the last 12 months
InsiderRoleSoldBoughtFilingsPre-arranged (10b5-1)Last filed
Michael F. MahoneyChairman, President & CEO$15.0M$9.0M2100% of sales
Joseph Michael FitzgeraldEVP & Group Pres, Cardiology$5.0M—1100% of sales
Ellen M. ZaneDirector$2.6M—2100% of sales
Arthur C. ButcherEVP& Grp Pres, MedSurg & APAC$1.8M—1100% of sales
Edward J. LudwigDirector—$430.3K2—
David C. HabigerDirector—$407.9K3—
Susan E. MoranoDirector—$100.4K1—
Cheryl PegusDirector—$100.0K1—
Other insider activity (not market trades) · 114 records
  • Option exercises44 records
  • Tax withholding37 records
  • Grants and awards20 records
  • Gifts7 records
  • Other6 records

Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.

Build this yourself

This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:

Agent prompt

Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for BSX every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.

How to read this page

Open-market purchase or sale
A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
Pre-arranged (10b5-1)
The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
Filing date
Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.